These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12442811)

  • 21. Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.
    Mohammad RM; al-Katib A; Pettit GR; Sensenbrenner LL
    Cancer Res; 1994 Jan; 54(1):165-8. PubMed ID: 8261437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapy of Waldenström´s macroglobulinaemia in the year 2014].
    Adam Z; Krejčí M; Pour L; Ševčíková E
    Vnitr Lek; 2014 Feb; 60(2):139-57. PubMed ID: 24754419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Waldenström's macroglobulinemia].
    Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
    Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
    Adam Z; Pour L; Krejčí M; Ševčíková S; Pourová E; Ševčíková E; Král Z; Mayer J
    Vnitr Lek; 2016 Jan; 62(1):25-39. PubMed ID: 26967234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.
    Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Zervas K; Tsatalas C; Kokkinis G; Repoussis P; Symeonidis A; Delimpasi S; Katodritou E; Vervessou E; Michali E; Pouli A; Gika D; Vassou A; Terpos E; Anagnostopoulos N; Economopoulos T; Pangalis G
    J Clin Oncol; 2007 Aug; 25(22):3344-9. PubMed ID: 17577016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.
    Ioakimidis L; Patterson CJ; Hunter ZR; Soumerai JD; Manning RJ; Turnbull B; Sheehy P; Treon SP
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):62-6. PubMed ID: 19362976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
    Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
    Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current options to manage Waldenström's macroglobulinemia.
    Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
    Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.
    Dimopoulos MA; Alexanian R; Gika D; Anagnostopoulos A; Zervas C; Zomas A; Kyrtsonis MC; Anagnostopoulos N; Pangalis GA; Weber DM
    Leuk Lymphoma; 2004 Oct; 45(10):2057-61. PubMed ID: 15370250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
    Kersten MJ; Amaador K; Minnema MC; Vos JMI; Nasserinejad K; Kap M; Kastritis E; Gavriatopoulou M; Kraan W; Chamuleau MED; Deeren D; Tick LW; Doorduijn JK; Offner F; Böhmer LH; Liu RD; Pals ST; Dimopoulos MA
    J Clin Oncol; 2022 Jan; 40(1):40-51. PubMed ID: 34388022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab.
    Uchino K; Sameshima H; Miyamoto T; Iino T; Kato K; Henzan H; Aoki K; Nagafuji K; Gondo H; Harada M
    Intern Med; 2004 Feb; 43(2):131-4. PubMed ID: 15005256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A SCID-hu in vivo model of human Waldenström macroglobulinemia.
    Tassone P; Neri P; Kutok JL; Tournilhac O; Santos DD; Hatjiharissi E; Munshi V; Venuta S; Anderson KC; Treon SP; Munshi NC
    Blood; 2005 Aug; 106(4):1341-5. PubMed ID: 15886318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment of cryoglobulinemic glomerulonephritis derived from Waldenström's macroglobulinemia by rituximab-CHOP and tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation.
    Kawano N; Ikeda N; Yoshida S; Sugio Y; Yamashita K; Uezono S; Hayashi T; Hara S; Makino S; Shimoda K; Ueda A
    Int J Hematol; 2010 Sep; 92(2):391-7. PubMed ID: 20686877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
    Weber DM; Dimopoulos MA; Delasalle K; Rankin K; Gavino M; Alexanian R
    Semin Oncol; 2003 Apr; 30(2):243-7. PubMed ID: 12720145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended rituximab therapy in Waldenström's macroglobulinemia.
    Treon SP; Emmanouilides C; Kimby E; Kelliher A; Preffer F; Branagan AR; Anderson KC; Frankel SR;
    Ann Oncol; 2005 Jan; 16(1):132-8. PubMed ID: 15598950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia.
    Buske C
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):821-827. PubMed ID: 30190020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Agranulocytosis Associated with Waldenström Macroglobulinemia.
    Vaxman I; Shepshelovich D; Hayman L; Raanani P; Lahav M
    Acta Haematol; 2018; 140(1):42-45. PubMed ID: 30114687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.
    Treon SP; Hanzis C; Tripsas C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):133-5. PubMed ID: 21454214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.